MediSpend and RLDatix Life Sciences, a part of RLDatix, have officially announced a deal to merge, creating a new company that will lead in innovation and compliance within the life sciences field. This partnership brings together their combined strengths to provide a wide range of software, data, and workflow solutions. These tools are designed to support every stage of compliance, transparency, and sales support for life sciences companies around the world. The new company serves over 300 clients in the pharmaceutical, biotechnology, and medical device industries globally.
Health Technology Insights: Medecision Acquires of Excell Healthcare Advisors
The new company is backed by major investors, including Five Arrows, which is part of Rothschild & Co’s alternative assets, Susquehanna Growth Equity, TA Associates, and Nordic Capital. This merger brings together RLDatix Life Sciences’ rich experience in pharmaceutical development, commercialization, distribution, and compliance with MediSpend’s innovative SaaS technology that focuses on transparency, stakeholder interaction, and clinical data management.
MediSpend provides advanced tools that help life sciences companies grow their business while ensuring they stay compliant. Their technology includes features for Stakeholder Engagement, Event Management, Spend Transparency, and advanced Clinical Data Document Anonymization and Redaction. On the other hand, RLDatix Life Sciences offers deep expertise in managing complex regulatory requirements, reducing risks, and maintaining high compliance standards in areas such as Government Pricing and Learning and Development.
Health Technology Insights: Iterative Health, One GI Partner to Advance Care Innovation
This strategic merger aims to speed up innovation and compliance efforts, helping pharmaceutical and life sciences companies deliver quality healthcare products more efficiently and ethically. The combination of these two companies is expected to help clients manage the complexities of compliance while improving operational performance.
Michael Allelunas, the CEO of the newly formed company, emphasized their commitment to delivering innovative software and services worldwide. He said, “By joining forces, we can offer a unified platform that improves global compliance, increases operational efficiency, and creates new opportunities for our customers.” Leigh Powell, the Chairman, expressed enthusiasm about combining capabilities and technology, stating, “This merger aligns our missions and strengthens our ability to serve the life sciences industry. We look forward to uniting our teams and customers to become the partner of choice moving forward.” Clients and partners can expect consistent service, increased investment in product development, and a smooth integration process. For now, both brand names will continue to be used, with plans to announce a unified brand name soon.
Health Technology Insights: Charles River Joins EASYGEN to Advance Bedside CAR-T Manufacturing
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
